# Official Journal C 410/1 De

| | ISSN 1977-091X |
| --- | --- |
| Official Journal
  of the European Union | C 410 |
| | |
| English edition | Information and Notices | Volume 601 December 2017 |

ISSN 1977-091X

Official Journal

of the European Union

C 410

English edition

Information and Notices

Volume 601 December 2017

---

| Notice No | Contents | page |
| --- | --- | --- |
| | IV   Notices |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2017/C 410/01 | Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 October 2017 to 31 October 2017(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council) | 1 |
| 2017/C 410/02 | Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 October 2017 to 31 October 2017(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC) | 5 |

Notice No

Contents

page

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2017/C 410/01

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 October 2017 to 31 October 2017(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

1

2017/C 410/02

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 October 2017 to 31 October 2017(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)

5

---

| EN | |
| --- | --- |

EN

---

IV Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

| 1.12.2017 | EN | Official Journal of the European Union | C 410/1 |
| --- | --- | --- | --- |

1.12.2017

EN

Official Journal of the European Union

C 410/1

---

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 October 2017 to 31 October 2017

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1))

(2017/C 410/01)

| — | Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted |
| --- | --- |

—

Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 3.10.2017 | Beromun | Boehringer Ingelheim International GmbH
  Binger Straße 173, 55216 Ingelheim am Rhein, Deutschland | EU/1/99/097 | 5.10.2017 |
| 3.10.2017 | Lantus | Sanofi-Aventis Deutschland GmbH
  D-65926 Frankfurt am Main, Deutschland | EU/1/00/134 | 5.10.2017 |
| 3.10.2017 | Ristaben | Merck Sharp & Dohme Limited
  Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom | EU/1/10/621 | 5.10.2017 |
| 3.10.2017 | Synflorix | GlaxoSmithKline Biologicals S.A.
  rue de l’Institut 89, 1330 Rixensart, Belgique | EU/1/09/508 | 5.10.2017 |
| 3.10.2017 | Toujeo | Sanofi-Aventis Deutschland GmbH
  D-65926 Frankfurt am Main, Deutschland | EU/1/00/133 | 5.10.2017 |
| 3.10.2017 | Zoely | Teva B.V.
  Swensweg 5, 2031 GA Haarlem, Nederland | EU/1/11/690 | 5.10.2017 |
| 4.10.2017 | Empliciti | Bristol-Myers Squibb Pharma EEIG
  Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, United Kingdom | EU/1/16/1088 | 6.10.2017 |
| 4.10.2017 | Twinrix Adult | GlaxoSmithKline Biologicals S.A.
  rue de l’Institut 89, 1330 Rixensart, Belgique | EU/1/96/020 | 6.10.2017 |
| 9.10.2017 | Ambirix | GlaxoSmithKline Biologicals S.A.
  rue de l’Institut 89, 1330 Rixensart, Belgique | EU/1/02/224 | 11.10.2017 |
| 9.10.2017 | Erivedge | Roche Registration Limited
  6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom | EU/1/13/848 | 11.10.2017 |
| 13.10.2017 | Amlodipine/Valsartan Mylan | Mylan S.A.S
  117 allée des Parcs, 69800 Saint Priest, France | EU/1/16/1092 | 17.10.2017 |
| 13.10.2017 | Emtricitabine/Tenofovir disoproxil Zentiva | Zentiva, k.s.
  U Kabelovny 130, 102 37 Praha 10, Česká republika | EU/1/16/1148 | 17.10.2017 |
| 13.10.2017 | JETREA | ThromboGenics NV
  Gaston Geenslaan 1, 3001 Leuven, België | EU/1/13/819 | 17.10.2017 |
| 13.10.2017 | Twinrix Paediatric | GlaxoSmithKline Biologicals S.A.
  rue de l’Institut 89, 1330 Rixensart, Belgique | EU/1/97/029 | 17.10.2017 |
| 13.10.2017 | Ulunar Breezhaler | Novartis Europharm Limited
  Frimley Business Park, Camberley GU16 7SR, United Kingdom | EU/1/14/917 | 17.10.2017 |
| 13.10.2017 | Wakix | Bioprojet Pharma
  9 rue Rameau, 75002 Paris, France | EU/1/15/1068 | 17.10.2017 |
| 19.10.2017 | Emend | Merck Sharp & Dohme Limited
  Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom | EU/1/03/262 | 24.10.2017 |
| 19.10.2017 | Firazyr | Shire Orphan Therapies GmbH
  Friedrichstraße 149, 10117 Berlin, Deutschland | EU/1/08/461 | 23.10.2017 |
| 19.10.2017 | Humalog | Eli Lilly Nederland B.V.
  Papendorpseweg 83, 3528 BJ Utrecht, Nederland | EU/1/96/007 | 23.10.2017 |
| 19.10.2017 | Mozobil | Genzyme Europe B.V.
  Gooimeer 10, 1411 DD Naarden, Nederland | EU/1/09/537 | 23.10.2017 |
| 19.10.2017 | Opdivo | Bristol-Myers Squibb Pharma EEIG
  Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, United Kingdom | EU/1/15/1014 | 23.10.2017 |
| 19.10.2017 | Pradaxa | Boehringer Ingelheim International GmbH
  Binger Straße 173, 55216 Ingelheim am Rhein, Deutschland | EU/1/08/442 | 23.10.2017 |
| 19.10.2017 | Revestive | Shire Pharmaceuticals Ireland Limited
  5 Riverwalk, Citywest Business Campus, Dublin 24, Ireland | EU/1/12/787 | 23.10.2017 |
| 19.10.2017 | Stribild | Gilead Sciences International Limited
  Cambridge CB21 6GT, United Kingdom | EU/1/13/830 | 23.10.2017 |
| 19.10.2017 | Xarelto | Bayer AG
  D-51368 Leverkusen, Deutschland | EU/1/08/472 | 23.10.2017 |
| 19.10.2017 | Yondelis | Pharma Mar S.A.
  Avenida de los Reyes 1, Polígono Industrial La Mina, 28770 Colmenar Viejo, Madrid, España | EU/1/07/417 | 23.10.2017 |
| 23.10.2017 | Giotrif | Boehringer Ingelheim International GmbH
  Binger Straße 173, 55216 Ingelheim am Rhein, Deutschland | EU/1/13/879 | 25.10.2017 |
| 23.10.2017 | Instanyl | Takeda Pharma A/S
  Dybendal Alle 10, 2630 Taastrup, Danmark | EU/1/09/531 | 25.10.2017 |
| 23.10.2017 | Levetiracetam Actavis Group | Actavis Group PTC ehf.
  Reykjavíkurvegi 76-78, 220 Hafnarfjörður, Íceland | EU/1/11/738 | 25.10.2017 |
| 23.10.2017 | Liprolog | Eli Lilly Nederland B.V.
  Papendorpseweg 83, 3528 BJ Utrecht, Nederland | EU/1/01/195 | 25.10.2017 |
| 23.10.2017 | Olanzapine Glenmark | Glenmark Pharmaceuticals Europe Limited
  Laxmi House, 2B Draycott Avenue, Kenton, Harrow, Middlesex, HA3 0BU, United Kingdom | EU/1/09/587 | 25.10.2017 |
| 23.10.2017 | Olanzapine Glenmark Europe | Glenmark Pharmaceuticals Europe Limited
  Laxmi House, 2B Draycott Avenue, Kenton, Harrow, Middlesex, HA3 0BU, United Kingdom | EU/1/09/588 | 25.10.2017 |
| 23.10.2017 | Prevenar 13 | Pfizer Limited
  Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom | EU/1/09/590 | 25.10.2017 |
| 30.10.2017 | Competact | Takeda Pharma A/S
  Dybendal Alle 10, 2630 Taastrup, Danmark | EU/1/06/354 | 1.11.2017 |
| 30.10.2017 | Epclusa | Gilead Sciences International Ltd
  Flowers Building, Granta Park, Abington, Cambridge CB21 6GT United Kingdom | EU/1/16/1116 | 1.11.2017 |
| 30.10.2017 | Firdapse | BioMarin Europe Ltd
  10 Bloomsbury Way, London WC1A 2SL, United Kingdom | EU/1/09/601 | 1.11.2017 |
| 30.10.2017 | Fortacin | Recordati Ireland Ltd
  Raheens East, Ringaskiddy, Co. Cork, Ireland | EU/1/13/881 | 1.11.2017 |
| 30.10.2017 | Ibandronic Acid Teva | Teva B.V.
  Swensweg 5, 2031 GA Haarlem, Nederland | EU/1/10/642 | 2.11.2017 |
| 30.10.2017 | Multaq | Sanofi-Aventis groupe
  54 rue La Boétie, 75008 Paris, France | EU/1/09/591 | 2.11.2017 |
| 30.10.2017 | Tarceva | Roche Registration Limited
  6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom | EU/1/05/311 | 1.11.2017 |
| 30.10.2017 | Ultibro Breezhaler | Novartis Europharm Limited
  Frimley Business Park, Camberley GU16 7SR, United Kingdom | EU/1/13/862 | 1.11.2017 |
| 30.10.2017 | Venclyxto | AbbVie Ltd
  Vanwall Road, Maidenhead, SL6 4UB, United Kingdom | EU/1/16/1138 | 1.11.2017 |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

3.10.2017

Beromun

Boehringer Ingelheim International GmbH

Binger Straße 173, 55216 Ingelheim am Rhein, Deutschland

EU/1/99/097

5.10.2017

3.10.2017

Lantus

Sanofi-Aventis Deutschland GmbH

D-65926 Frankfurt am Main, Deutschland

EU/1/00/134

5.10.2017

3.10.2017

Ristaben

Merck Sharp & Dohme Limited

Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom

EU/1/10/621

5.10.2017

3.10.2017

Synflorix

GlaxoSmithKline Biologicals S.A.

rue de l’Institut 89, 1330 Rixensart, Belgique

EU/1/09/508

5.10.2017

3.10.2017

Toujeo

Sanofi-Aventis Deutschland GmbH

D-65926 Frankfurt am Main, Deutschland

EU/1/00/133

5.10.2017

3.10.2017

Zoely

Teva B.V.

Swensweg 5, 2031 GA Haarlem, Nederland

EU/1/11/690

5.10.2017

4.10.2017

Empliciti

Bristol-Myers Squibb Pharma EEIG

Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, United Kingdom

EU/1/16/1088

6.10.2017

4.10.2017

Twinrix Adult

GlaxoSmithKline Biologicals S.A.

rue de l’Institut 89, 1330 Rixensart, Belgique

EU/1/96/020

6.10.2017

9.10.2017

Ambirix

GlaxoSmithKline Biologicals S.A.

rue de l’Institut 89, 1330 Rixensart, Belgique

EU/1/02/224

11.10.2017

9.10.2017

Erivedge

Roche Registration Limited

6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom

EU/1/13/848

11.10.2017

13.10.2017

Amlodipine/Valsartan Mylan

Mylan S.A.S

117 allée des Parcs, 69800 Saint Priest, France

EU/1/16/1092

17.10.2017

13.10.2017

Emtricitabine/Tenofovir disoproxil Zentiva

Zentiva, k.s.

U Kabelovny 130, 102 37 Praha 10, Česká republika

EU/1/16/1148

17.10.2017

13.10.2017

JETREA

ThromboGenics NV

Gaston Geenslaan 1, 3001 Leuven, België

EU/1/13/819

17.10.2017

13.10.2017

Twinrix Paediatric

GlaxoSmithKline Biologicals S.A.

rue de l’Institut 89, 1330 Rixensart, Belgique

EU/1/97/029

17.10.2017

13.10.2017

Ulunar Breezhaler

Novartis Europharm Limited

Frimley Business Park, Camberley GU16 7SR, United Kingdom

EU/1/14/917

17.10.2017

13.10.2017

Wakix

Bioprojet Pharma

9 rue Rameau, 75002 Paris, France

EU/1/15/1068

17.10.2017

19.10.2017

Emend

Merck Sharp & Dohme Limited

Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom

EU/1/03/262

24.10.2017

19.10.2017

Firazyr

Shire Orphan Therapies GmbH

Friedrichstraße 149, 10117 Berlin, Deutschland

EU/1/08/461

23.10.2017

19.10.2017

Humalog

Eli Lilly Nederland B.V.

Papendorpseweg 83, 3528 BJ Utrecht, Nederland

EU/1/96/007

23.10.2017

19.10.2017

Mozobil

Genzyme Europe B.V.

Gooimeer 10, 1411 DD Naarden, Nederland

EU/1/09/537

23.10.2017

19.10.2017

Opdivo

Bristol-Myers Squibb Pharma EEIG

Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, United Kingdom

EU/1/15/1014

23.10.2017

19.10.2017

Pradaxa

Boehringer Ingelheim International GmbH

Binger Straße 173, 55216 Ingelheim am Rhein, Deutschland

EU/1/08/442

23.10.2017

19.10.2017

Revestive

Shire Pharmaceuticals Ireland Limited

5 Riverwalk, Citywest Business Campus, Dublin 24, Ireland

EU/1/12/787

23.10.2017

19.10.2017

Stribild

Gilead Sciences International Limited

Cambridge CB21 6GT, United Kingdom

EU/1/13/830

23.10.2017

19.10.2017

Xarelto

Bayer AG

D-51368 Leverkusen, Deutschland

EU/1/08/472

23.10.2017

19.10.2017

Yondelis

Pharma Mar S.A.

Avenida de los Reyes 1, Polígono Industrial La Mina, 28770 Colmenar Viejo, Madrid, España

EU/1/07/417

23.10.2017

23.10.2017

Giotrif

Boehringer Ingelheim International GmbH

Binger Straße 173, 55216 Ingelheim am Rhein, Deutschland

EU/1/13/879

25.10.2017

23.10.2017

Instanyl

Takeda Pharma A/S

Dybendal Alle 10, 2630 Taastrup, Danmark

EU/1/09/531

25.10.2017

23.10.2017

Levetiracetam Actavis Group

Actavis Group PTC ehf.

Reykjavíkurvegi 76-78, 220 Hafnarfjörður, Íceland

EU/1/11/738

25.10.2017

23.10.2017

Liprolog

Eli Lilly Nederland B.V.

Papendorpseweg 83, 3528 BJ Utrecht, Nederland

EU/1/01/195

25.10.2017

23.10.2017

Olanzapine Glenmark

Glenmark Pharmaceuticals Europe Limited

Laxmi House, 2B Draycott Avenue, Kenton, Harrow, Middlesex, HA3 0BU, United Kingdom

EU/1/09/587

25.10.2017

23.10.2017

Olanzapine Glenmark Europe

Glenmark Pharmaceuticals Europe Limited

Laxmi House, 2B Draycott Avenue, Kenton, Harrow, Middlesex, HA3 0BU, United Kingdom

EU/1/09/588

25.10.2017

23.10.2017

Prevenar 13

Pfizer Limited

Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom

EU/1/09/590

25.10.2017

30.10.2017

Competact

Takeda Pharma A/S

Dybendal Alle 10, 2630 Taastrup, Danmark

EU/1/06/354

1.11.2017

30.10.2017

Epclusa

Gilead Sciences International Ltd

Flowers Building, Granta Park, Abington, Cambridge CB21 6GT United Kingdom

EU/1/16/1116

1.11.2017

30.10.2017

Firdapse

BioMarin Europe Ltd

10 Bloomsbury Way, London WC1A 2SL, United Kingdom

EU/1/09/601

1.11.2017

30.10.2017

Fortacin

Recordati Ireland Ltd

Raheens East, Ringaskiddy, Co. Cork, Ireland

EU/1/13/881

1.11.2017

30.10.2017

Ibandronic Acid Teva

Teva B.V.

Swensweg 5, 2031 GA Haarlem, Nederland

EU/1/10/642

2.11.2017

30.10.2017

Multaq

Sanofi-Aventis groupe

54 rue La Boétie, 75008 Paris, France

EU/1/09/591

2.11.2017

30.10.2017

Tarceva

Roche Registration Limited

6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom

EU/1/05/311

1.11.2017

30.10.2017

Ultibro Breezhaler

Novartis Europharm Limited

Frimley Business Park, Camberley GU16 7SR, United Kingdom

EU/1/13/862

1.11.2017

30.10.2017

Venclyxto

AbbVie Ltd

Vanwall Road, Maidenhead, SL6 4UB, United Kingdom

EU/1/16/1138

1.11.2017

| — | Modification of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted |
| --- | --- |

—

Modification of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 5.10.2017 | Equisolon | Le Vet B.V.
  Wilgenweg 7, 3421 TV Oudewater, Nederland | EU/2/14/161 | 10.10.2017 |
| 10.10.2017 | Simparica | Zoetis Belgium S.A.
  rue Laid Burniat 1, 1348 Louvain-la-Neuve, Belgique | EU/2/15/191 | 12.10.2017 |
| 19.10.2017 | Bovela | Boehringer Ingelheim International GmbH
  Binger Straße 173, 55216 Ingelheim am Rhein, Deutschland | EU/2/14/176 | 23.10.2017 |
| 24.10.2017 | Inflacam | Chanelle Pharmaceuticals Manufacturing Limited
  Loughrea, Co. Galway, Ireland | EU/2/11/134 | 26.10.2017 |
| 24.10.2017 | Ingelvac CircoFLEX | Boehringer Ingelheim Vetmedica GmbH
  D-55216 Ingelheim am Rhein, Deutschland | EU/2/07/079 | 26.10.2017 |
| 31.10.2017 | Pexion | Boehringer Ingelheim Vetmedica GmbH
  D-55216 Ingelheim am Rhein, Deutschland | EU/2/12/147 | 6.11.2017 |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

5.10.2017

Equisolon

Le Vet B.V.

Wilgenweg 7, 3421 TV Oudewater, Nederland

EU/2/14/161

10.10.2017

10.10.2017

Simparica

Zoetis Belgium S.A.

rue Laid Burniat 1, 1348 Louvain-la-Neuve, Belgique

EU/2/15/191

12.10.2017

19.10.2017

Bovela

Boehringer Ingelheim International GmbH

Binger Straße 173, 55216 Ingelheim am Rhein, Deutschland

EU/2/14/176

23.10.2017

24.10.2017

Inflacam

Chanelle Pharmaceuticals Manufacturing Limited

Loughrea, Co. Galway, Ireland

EU/2/11/134

26.10.2017

24.10.2017

Ingelvac CircoFLEX

Boehringer Ingelheim Vetmedica GmbH

D-55216 Ingelheim am Rhein, Deutschland

EU/2/07/079

26.10.2017

31.10.2017

Pexion

Boehringer Ingelheim Vetmedica GmbH

D-55216 Ingelheim am Rhein, Deutschland

EU/2/12/147

6.11.2017

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

| European Medicines Agency |
| --- |
| 30 Churchill Place |
| Canary Wharf |
| London E14 5EU |
| United Kingdom |

European Medicines Agency

30 Churchill Place

Canary Wharf

London E14 5EU

United Kingdom

---

(1)  OJ L 136, 30.4.2004, p. 1.

---

| 1.12.2017 | EN | Official Journal of the European Union | C 410/5 |
| --- | --- | --- | --- |

1.12.2017

EN

Official Journal of the European Union

C 410/5

---

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 October 2017 to 31 October 2017

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC (1) or Article 38 of Directive 2001/82/EC (2))

(2017/C 410/02)

| — | Issuing, maintenance or modification of a national marketing authorisation |
| --- | --- |

—

Issuing, maintenance or modification of a national marketing authorisation

| Date of the decision | Name(s) of the medicinal product | INN (International Non-Proprietary Name) | Holder(s) of the marketing authorisation | Member State concerned | Date of notification |
| --- | --- | --- | --- | --- | --- |
| 5.10.2017 | Lincocin and its associated names | Lincomycin | See Annex I | See Annex I | 9.10.2017 |

Date of the decision

Name(s) of the medicinal product

INN (International Non-Proprietary Name)

Holder(s) of the marketing authorisation

Member State concerned

Date of notification

5.10.2017

Lincocin and its associated names

Lincomycin

See Annex I

See Annex I

9.10.2017

---

(1)  OJ L 311, 28.11.2001, p. 67.

(2)  OJ L 311, 28.11.2001, p. 1.

---

ANNEX I

List of the names, pharmaceutical form, strength of the veterinary medicinal products, animal species, route of administration, marketing authorisation holders in the Member States

| Member State EU/EEA | Marketing authorisation holder | Name | INN | Strength | Pharmaceutical form | Animal species | Route of administration |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Belgium | Zoetis Belgium SA
  Rue Laid Burniat 1
  1348 Louvain-la-Neuve
  Belgium | Lincocin 40 % | Lincomycin (as lincomycin hydrochloride) | 400 mg/g | Powder for oral solution | Pigs, poultry (broilers) | Oral use (via drinking water) |
| Denmark | Zoetis Finland Oy
  Tietokuja 4
  00330 Helsinki
  Finland | Lincocin Vet | Lincomycin hydrochloride | 400 mg/g | Powder for oral solution | Pigs | Oral |
| France | Zoetis France
  10 rue Raymond David
  92240 Malakoff
  France | LINCOCINE POUDRE SOLUBLE | Lincomycin hydrochloride | 400 mg/g | Powder for oral solution | Pigs, chickens | Oral |
| Germany | Zoetis Deutschland GmbH
  Schellingstr. 1
  D-10785 Berlin
  Germany | Albiotic Pulver 400 mg/g zum Eingeben über das Trinkwasser für Schweine | Lincomycin hydrochloride | 470,6  mg lincomycin HCl/g (corresponding to 400 mg lincomycin/g) | powder for use in drinking water | Pigs | Oral |
| Hungary | Zoetis Hungary Kft.
  Budapest, Alkotás u. 53., 1123 Hungary | Lincocin 400 mg/g por belsőleges oldathoz A.U.V. | Lincomycin hydrochloride | 400 mg/g | Powder for oral solution | Pigs, chickens | In drinking water use |
| Ireland | Zoetis Belgium S.A
  2nd Floor, Building 10
  Cherrywood Business Park
  Loughlinstown
  Co. Dublin
  Ireland | Lincocin Soluble Powder | Lincomycin hydrochloride | 400 mg/g | Powder for oral solution | Pigs | Oral via the drinking water |
| Poland | Zoetis Polska Sp. z o.o.
  Postępu 17B
  02-676 Warsaw
  Poland | Lincocin 40 % 400 mg/g proszek do sporządzania roztworu doustnego dla świń i kur | Lincomycin (as lincomycin hydrochloride) | 400 mg/g | Powder for oral solution | Pigs, chickens | In drinking water use |
| United Kingdom | Zoetis UK Limited
  5th Floor, 6 St. Andrew Street
  London EC4A 3AE
  United Kingdom | Lincocin Soluble Powder 400 mg/g Powder for Oral Solution | Lincomycin | 400 mg/g | Powder for oral solution | Pigs | In drinking water use |

Member State EU/EEA

Marketing authorisation holder

Name

INN

Strength

Pharmaceutical form

Animal species

Route of administration

Belgium

Zoetis Belgium SA

Rue Laid Burniat 1

1348 Louvain-la-Neuve

Belgium

Lincocin 40 %

Lincomycin (as lincomycin hydrochloride)

400 mg/g

Powder for oral solution

Pigs, poultry (broilers)

Oral use (via drinking water)

Denmark

Zoetis Finland Oy

Tietokuja 4

00330 Helsinki

Finland

Lincocin Vet

Lincomycin hydrochloride

400 mg/g

Powder for oral solution

Pigs

Oral

France

Zoetis France

10 rue Raymond David

92240 Malakoff

France

LINCOCINE POUDRE SOLUBLE

Lincomycin hydrochloride

400 mg/g

Powder for oral solution

Pigs, chickens

Oral

Germany

Zoetis Deutschland GmbH

Schellingstr. 1

D-10785 Berlin

Germany

Albiotic Pulver 400 mg/g zum Eingeben über das Trinkwasser für Schweine

Lincomycin hydrochloride

470,6  mg lincomycin HCl/g (corresponding to 400 mg lincomycin/g)

powder for use in drinking water

Pigs

Oral

Hungary

Zoetis Hungary Kft.

Budapest, Alkotás u. 53., 1123 Hungary

Lincocin 400 mg/g por belsőleges oldathoz A.U.V.

Lincomycin hydrochloride

400 mg/g

Powder for oral solution

Pigs, chickens

In drinking water use

Ireland

Zoetis Belgium S.A

2nd Floor, Building 10

Cherrywood Business Park

Loughlinstown

Co. Dublin

Ireland

Lincocin Soluble Powder

Lincomycin hydrochloride

400 mg/g

Powder for oral solution

Pigs

Oral via the drinking water

Poland

Zoetis Polska Sp. z o.o.

Postępu 17B

02-676 Warsaw

Poland

Lincocin 40 % 400 mg/g proszek do sporządzania roztworu doustnego dla świń i kur

Lincomycin (as lincomycin hydrochloride)

400 mg/g

Powder for oral solution

Pigs, chickens

In drinking water use

United Kingdom

Zoetis UK Limited

5th Floor, 6 St. Andrew Street

London EC4A 3AE

United Kingdom

Lincocin Soluble Powder 400 mg/g Powder for Oral Solution

Lincomycin

400 mg/g

Powder for oral solution

Pigs

In drinking water use

---